Company Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE
Equities
PLX
US74365A3095
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
732.5 ILa | -.--% | +3.29% | +69.68% |
10/05 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
10/05 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Recombinant Therapeutic Proteins
100.0
%
| 48 | 100.0 % | 38 | 100.0 % | -19.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Global
56.3
%
| 22 | 46.9 % | 22 | 56.3 % | -3.33% |
United States
26.5
%
| 12 | 26.0 % | 10 | 26.5 % | -18.08% |
Brazil
16.7
%
| 9 | 19.8 % | 6 | 16.7 % | -32.29% |
Italy
0.5
%
| 3 | 7.2 % | 0 | 0.5 % | -94.50% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30/19/30 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22/19/22 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05/20/05 |
Yaron Naos
COO | Chief Operating Officer | 60 | 01/04/01 |
Gina Balderas
PRN | Corporate Officer/Principal | - | - |
Fellous Yael
HRO | Human Resources Officer | - | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01/19/01 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01/19/01 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01/14/01 |
Amos Bar Shalev
BRD | Director/Board Member | 71 | 01/08/01 |
Eliot Forster
CHM | Chairman | 58 | 14/23/14 |
Shmuel Ben Zvi
BRD | Director/Board Member | 64 | 30/22/30 |
Dror Bashan
CEO | Chief Executive Officer | 57 | 30/19/30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 73,316,084 | 62,627,738 ( 85.42 %) | 0 | 85.42 % |
Company contact information
Protalix Biotherapeutics, Inc.
2 University Plaza Suite 100
07601, Hackensack
+972 4 902 8100
http://www.protalix.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- PLX Stock
- PLX Stock
- Company Protalix BioTherapeutics, Inc.